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 Letter to the editor editoriaLs: CeLL CyCLe Features
Long-term survival of ovarian cancer 
patients is poor due to lack of early detec-
tion and high rates of therapeutic failure 
and chemoresistance. It is estimated that 
15,500 women in the United States will 
die of ovarian cancer this year, and that 
nearly 23,000 more will receive a first-
time diagnosis, 67% of whom will pres-
ent with advanced stage disease (stages III 
and IV).1,2 Only 5,200 of those are expected 
to survive more than 5 y due to the mark-
edly few alternative therapies currently 
available for platinum-resistant tumors.2,3 
While the mechanism underlying plati-
num chemoresistance in ovarian cancer is 
extremely complex, drug-resistant cancer 
stem cells (CSCs), which evade the sys-
temic effects of standard chemotherapies, 
are a major contributor to platinum-resis-
tant disease.4-7 Consequently, a cure likely 
necessitates the targeting and sensitization 
of CSCs in newly diagnosed tumors and 
makes the identification of key pathways 
for CSC function a necessity in present 
day cancer research.5
We recently developed a functional 
and molecular profile of ovarian CSCs to 
identify both stem cell surface markers 
and key pathways critical for CSC func-
tion.7 It is important to note, however, 
that none of the markers we identified, 
including CD44, CD24, CD133 and 
ALDH1, appear to be completely spe-
cific for the isolation of ovarian CSCs.7 
In contrast, we found the side popula-
tion (SP) phenotype to be an extremely 
reliable marker for the identification and 
characterization of tumor cells enriched 
for CSCs in a large number of experi-
ments involving both murine and human 
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samples.7 Multiple studies have demon-
strated that SP cells can be sorted from 
tumors based on their ability to efflux the 
Hoechst dye.4,7 However, the accuracy of 
this method has been questioned at times, 
based on the incorrect assumption that 
the Hoechst dye may alter the cell cycle. 
Contrary to this assumption, our analy-
sis of stained and unstained cells using 
the Modfit LT software demonstrated no 
difference between the cell cycles of the 
two populations, indicating that the opti-
mized Hoechst staining is in fact a useful 
tool for the isolation and characterization 
of CSCs.
In characterizing the CSC profile, we 
have further established that Notch sig-
naling, which has been implicated in the 
maintenance of tissue homeostasis by 
regulating self-renewal of stem cells and 
differentiation of progenitor cells, is a key 
pathway for CSC function. Dysregulation 
of Notch signaling can lead to transforma-
tion of normal stem cells and/or acquisition 
of self-renewing ability in early progenitor 
cells during tumorigenesis. Within the 
Notch pathway, Notch 3 amplification 
has been correlated with tumor recur-
rence, chemoresistance to carboplatin 
and a poor prognostic outcome.6-8 Some 
data even suggest that activation of the 
Notch 3 pathway may reprogram tumor 
cells to assume a stem cell-like profile and 
contribute to platinum chemoresistance in 
ovarian cancer.6,7 Thus, we have recently 
shown that overexpression of a constitu-
tively activated Notch 3 receptor expands 
the number of CSCs and increases che-
moresistance to platinum compounds.7 
In contrast, inhibition of Notch 3 activity 
using either siRNAs or γ-secretase inhibi-
tors (GSI) sensitizes ovarian cancer cells to 
platinum-based therapies.6,7 Furthermore, 
our previous findings have indicated that 
a dual combination of GSI and cispla-
tin (CDDP) therapy, which targets both 
CSCs and non-CSCs, is a much more 
effective treatment than CDDP alone 
(Fig. 1), for both platinum-sensitive and 
-resistant patient samples.7
However, as this increased sensitivity 
is only observed in tumors with Notch 3 
overexpression and activation of the 
Notch pathway, the use of genetic bio-
markers to identify which patients are 
most likely to benefit from GSI-based 
therapy is critical. Beyond patient screen-
ing, a second critical element for success-
ful clinical trials is the use of functionally 
similar compounds in both research and 
clinic. This is of particular concern with 
GSIs, as there are over 20 different com-
pounds available for research and clinical 
use, the efficacy and toxicity of which var-
ies greatly. Of additional concern is the 
use of GSI monotherapy as a treatment 
strategy in clinical trials. Although GSI 
is effective in sensitizing cells to cytotoxic 
agents, such as platinum compounds, it 
does not contribute to long-term remis-
sion when used alone.7 Our data further 
suggest that Notch inhibitors should be 
used as a first line of treatment in combi-
nation with platinum in order to achieve 
the best results therapeutically.7 Finally, 
it is important to identify a Notch-based 
signature to better assess drug responses 
in clinical trials. Failure to address these 
guidelines likely played a significant role 
in the lack of success of two recently 192  Cell Cycle  Volume 12 issue 2
response to platinum treatment. The over-
whelming potential of Notch-based cancer 
treatments cannot be ignored. Increasing 
the use of personalized tumor biomarkers 
and translating these novel therapies into 
practice hold great promise for achieving a 
better prognosis in ovarian cancer.
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gastrointestinal toxicity and off-target 
effects.9 In an attempt to remedy this 
issue, inhibitory antibodies have recently 
been synthesized for all Notch receptors, 
including Notch 3.10 This will pave the 
way for new clinical trials to evaluate the 
efficacy of more selective and less toxic 
antibody-based therapies in enhancing the 
completed clinical trials using GSIs, which 
resulted in one GSI compound being dis-
continued indefinitely.9 Consequently, it 
is important that clinical trials replicate 
the design of successful preclinical studies 
whenever possible.
A further challenge to the clini-
cal application of GSIs has been their 
Figure 1. Cancer stem cells (CsCs) are key contributors to tumor chemoresistance due to their 
ability to survive platinum-based chemotherapies. Pictured is a graphical representation of 
a Notch-dependent ovarian tumor that accumulates drug-resistant CsCs (green circles) and 
acquires platinum resistance. differentiated Notch-dependent non-CsC tumor cells are shown in 
light blue circles. Mcauliffe et al.7 shows that tumor sensitivity to platinum is restored when the 
γ-secretase complex (plum), which cleaves and activates the Notch receptor (red), is targeted with 
γ-secretase inhibitor i (Gsi, navy blue triangles).